JOHN MAURICE DIETSCHY, MD
Osteopathic Medicine at Harry Hines Blvd, Dallas, TX

6835866, Dec 28, 2004

Dec 10, 1999

09/460292

David J. Mangelsdorf - Dallas TX
Joyce J. Repa - Dallas TX
Stephen D. Turley - Dallas TX
John M. Dietschy - Dallas TX

Board of Regents, The University of Texas Systems - Austin TX

C12P 2100

800 18, 800 4, 800 8, 800 9, 800 13, 435325

The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXR gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies.

8007994, Aug 30, 2011

Dec 22, 2004

11/021728

David J. Mangelsdorf - Dallas TX, US
Joyce J. Repa - Dallas TX, US
Stephen D. Turley - Dallas TX, US
John M. Dietschy - Dallas TX, US

The Board of Regents of the University of Texas System - Austin TX

C12N 5/00, C12N 15/00, G01N 33/53, C12Q 1/00

435 4, 435 71, 435455, 435375

The present invention relates to compositions and methods for reducing cholesterolemia and its effects. More specifically, the invention is directed, in one embodiment, to methods for screening for compounds that affect cholesterol levels generally, and in particular, that affect the absorption of cholesterol. The invention also is directed to methods of screening for compounds that increase bile acid synthesis. In so doing, the inventors describe useful transgenic cells and animals which lack one or both alleles of the LXRα gene. Also provided are therapeutic methods designed to reduce cholesterol levels in suitable subjects. The reduction may be effected by decreasing cholesterol absorption, increasing bile acid synthesis, or combinations thereof. Particularly useful in decreasing cholesterol absorption are RXR agonists, for example, rexinoid compounds. Therapeutic intervention in cholesterol biosynthesis and diet are additional adjunct therapies.